Neutralization of IL-6 Bioactivity for Attenuation of Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage

    loading  Checking for direct PDF access through Ovid



The aim of the current study was to prove the potential power of interleukin (IL)-6 antibody to attenuate vasospasm after bleeding in a cerebral artery model.


Group 1 (n=10) consisted of normal controls; group 2 (n=20) underwent microsurgical exposure of the atlantooccipital membrane and saline injection into the cisterna magna; and the remaining 40 rats were subjected to blood injection into the cisterna magna. Each of these 40 rats was randomly assigned to either the blood-injection only group (group 3, n=20) or the blood injection plus IL-6 antibody treatment group (group 4, n=20). Half of the rats from each of groups 2, 3, and 4 were killed on Day 2 and the other half on Day 5 after injection, and the inner diameters of the basilar artery and the middle cerebral artery were measured under a surgical microscope.


Two doses (10 μg) of IL-6 antibody did not affect the diameter of the middle cerebral artery and the basilar artery when testing was performed on Day 2 after subarachnoid hemorrhage (SAH). On the other hand, administering 5 doses (25 μg) of IL-6 antibody resulted in a significant increase in the diameter of the arteries compared with that seen in the untreated subgroup on Day 5 after SAH.


Parenteral multiple delayed dosing of IL-6 antibody is of benefit to attenuate vasospasm after SAH in the rat cerebral artery model, and future parenteral delayed dosing studies are needed to prove the potential power of IL-6 antibody in a cerebral vasospasm model.

Related Topics

    loading  Loading Related Articles